Cargando…

Second-generation antipsychotics and metabolic side-effects: Canadian population-based study

BACKGROUND: Use of second-generation antipsychotics (SGA) has increased in recent years; however, their use and effect on metabolic outcomes has been poorly characterised in population-level studies. AIMS: This study aimed to determine the associations between SGA use and metabolic indicators in a g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirsch, Lauren, Patten, Scott B., Bresee, Lauren, Jette, Nathalie, Pringsheim, Tamara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2018
Materias:	Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060488/ https://www.ncbi.nlm.nih.gov/pubmed/29998821 http://dx.doi.org/10.1192/bjo.2018.33

Ejemplares similares

Smoking, alcohol and drug use in youth and adults with attention-deficit hyperactivity disorder
por: Osland, Sydney, et al.
Publicado: (2017)

Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine
por: Boyda, Heidi N., et al.
Publicado: (2013)

A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models
por: Boyda, Heidi N., et al.
Publicado: (2021)

Prevalence of neurological conditions across the continuum of care based on interRAI assessments
por: Danila, Oana, et al.
Publicado: (2014)

Intentional Recreational Abuse of Quetiapine Compared to Other Second-generation Antipsychotics
por: Klein, Lauren, et al.
Publicado: (2017)

Guidelines for dementia or Parkinson’s disease with depression or anxiety: a systematic review
por: Goodarzi, Zahra, et al.
Publicado: (2016)

Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects
por: Rognoni, Carla, et al.
Publicado: (2021)

The Effect of Long-Term Second-Generation Antipsychotics Use on the Metabolic Syndrome Parameters in Jordanian Population
por: Abo Alrob, Osama, et al.
Publicado: (2019)

Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics
por: Rice, Jessie, et al.
Publicado: (2020)

Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
por: Grajales, Diana, et al.
Publicado: (2019)

Some side effects and effcts on physical activity of second-generation antipsychotics: A study in children and adolescents
por: Arman, Soroor, et al.
Publicado: (2014)

A Longitudinal Study of Relation between Side-effects and Clinical Improvement in Schizophrenia: Is There a Neuro-metabolic Threshold for Second Generation Antipsychotics?
por: Venkatasubramanian, Ganesan, et al.
Publicado: (2013)

The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study
por: Bodnar, Michael, et al.
Publicado: (2016)

Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
por: Divac, Nevena, et al.
Publicado: (2014)

Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management
por: Krill, Rebecca A, et al.
Publicado: (2014)

Comparison between characteristics of patients experiencing Extrpyramidal side effects, between first and second generation antipsychotic use- A retrospective cross sectional study.
por: Anjana., A, et al.
Publicado: (2022)

Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics
por: Gautam, Shiv, et al.
Publicado: (2011)

Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome
por: Skonieczna-Żydecka, Karolina, et al.
Publicado: (2018)

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs
por: Adkins, Daniel E., et al.
Publicado: (2010)

Arterial Stiffness in Patients Taking Second-generation Antipsychotics
por: Fındıklı, Ebru, et al.
Publicado: (2016)

Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
por: Caruso, Giuseppe, et al.
Publicado: (2020)

Movement Disorders in Elderly Users of Risperidone and First Generation Antipsychotic Agents: A Canadian Population-Based Study
por: Vasilyeva, Irina, et al.
Publicado: (2013)

First-generation vs second-generation antipsychotic drugs: The ongoing saga
por: Gupta, Sumeet
Publicado: (2010)

Monitoring side-effects of antipsychotics using the glasgow antipsychotic side-effect scale
por: Sterritt, James
Publicado: (2021)

The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
por: Tandon, Rajiv, et al.
Publicado: (2020)

Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics
por: Jeong, Seong Hoon, et al.
Publicado: (2018)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
por: Fang, Xinyu, et al.
Publicado: (2019)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study
por: Højlund, Mikkel, et al.
Publicado: (2020)

Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment Failure in a Population-Based Cohort
por: Janzen, Donica, et al.
Publicado: (2022)

Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study
por: Cothros, Nicholas, et al.
Publicado: (2019)

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics
por: Oh, Jee-Eun, et al.
Publicado: (2012)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Overcoming barriers to monitoring patients taking second-generation antipsychotics
por: Peña, Anita, et al.
Publicado: (2018)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

Combination treatment with second generation antipsychotics other than clozapine
por: Schmidt-Kraepelin, C.
Publicado: (2021)

Risk of Breast Cancer in Association with the Use of Second-generation Antipsychotics
por: Joo, Sung Woo, et al.
Publicado: (2022)

Factors Influencing the Use of Second-Generation Antipsychotics in Children with Psychosis
por: Ramachandran, Sujith, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k1fir3gn866vvrvhfa7er897st